Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
NCT07492927
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Clinically Significant Prostate Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Xijing Hospital
- Last updated on ClinicalTrials.gov
- March 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Illinois · 1
- Northwestern Memorial Hospital · Chicago, IL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.